

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid
OMB control number.

SUBSTITUTE FOR FORM 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE AS MANY SHEETS AS NECESSARY)					ATTY. DOCKET NO.: 2002.750 US	SERIAL NO.: 10/540,336
					APPLICANT: CORNELIS MARIUS TIMMERS ET AL.	
					EXAMINER NAME: David K. O'Dell	
					FILING DATE: 01/10/2006	ART UNIT: 1625
Sheet 1 of 4						
U.S. PATENT DOCUMENTS						
*EXAMINER INITIAL	CITE NO. ¹	DOCUMENT NUMBER	PUB. DATE. mm-dd-yyyy	NAME OF PATENTEE OR APPLICANT	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	AA	2004/0236190	1/02/2004	Van Straten		
	AB	2006/0142334	01/10/2006	Cornelis Marius Timmers		
	AC	2006/0167047	07/27/2006	Cornelis Marius Timmers		
FOREIGN PATENT DOCUMENTS						
*EXAMINER INITIAL	CITE NO. ¹	DOCUMENT NUMBER	PUB. DATE. mm-dd-yyyy	NAME OF PATENTEE OR APPLICANT	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	AD	WO 96/019458	06/27/1996	Ligand Pharmaceuticals		
Examiner signature:				Date considered:		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14.

This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUBSTITUTE FOR FORM 1449/PTO		ATTY. DOCKET NO.: 2002.750 US	SERIAL NO.: 10/540,336
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT: CORNELIS MARIUS TIMMERS ET AL.	
(USE AS MANY SHEETS AS NECESSARY)		EXAMINER NAME: David K. O'Dell	
		FILING DATE: 01/10/2006	ART UNIT: 1625

Sheet 2 of 4

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner initials*	Cite no. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AE	CAS 327981-38-4	
	AF	CAS 360760-14-1	
	AG	CAS 299418-67-0	
	AH	CAS 299970-20-0	
	AI	CHEMICAL ABSTRACTS, vol. 79, no. 9, September 3, 1973, Columbux, Ohio, US; abstract no 53152; LUGOVIK, B. A. ET AL: "Structure of compounds obtained from the interaction of 1, 2-dihydroquinolines with alkylbenzenes"	
	AJ	CHEMICAL ABSTRACTS, vol. 77, no. 25, December 18, 1972, Columbus, Ohio, US: abstract no. 164415, LUGOVIK, B.A.ET AL: "Reaction of 1, 2-dihydroquonolines with benzene and halobenzenes"	
	AK	CHEMICAL ABSTRACTS, vol. 105, no. 7, August 18, 1986, Columbus, Ohio, US; abstract no. 56990, SHMYREVA, ZH. V. ET AL: "Modification of anion exchanger Fuolite A 368 PR for the covalent immobilization of glucoamylase"	
	AL	CHEMICAL ABSTRACTS, "AMBINTER SCREENING COLLECTION", May 31, 2001	
	AM	CHEMICAL ABSTRACTS, Columbus Ohio, "VITAS-M SCREENING COLLECTION", March 22, 2001	
	AN	Atanes et. al., "Synthesis of 7-Substituted Dehydronoraporphines, with some Biogenetic Considerations," <i>Tetrahedron</i> 50 (1994) 11257-11266.	
	AO	Barmettler et. al., "Acid-Catalyzed [3,3]-Sigmatropic Rearrangements of N-Propargylanilines," <i>Helv. Chim. Acta</i> 73 (1990) 1515-1573.	
	AP	Bonnat et. al., "The Solid Phase Synthesis of a Guanidinium Based 'Tweezer' Receptor," <i>Tetrahedron Lett.</i> 37 (1996) 5409-5412.	
	AQ	Bouyssou et. al., "Synthesis of 7- and 5,7-Substituted-6-fluoro-2-methyl-1,2,3,4-tetrahydroquinolines: Convenient Precursors of Quinolone Antibacterial Agents," <i>J. Heterocycl. Chem.</i> 29 (1992) 895-898.	
	AR	Cerfontain et. al., "The Positional Reactivity Order in the Sulfur Trioxide Sulfonation of Benzene and Naphthalene Derivatives Containing an Electron-Withdrawing Substituent," <i>Recl. Trav. Chim. Pays-Bas</i> , 113 (1994) 403-410.	
	AS	Coppock, A., "New Synthesis of Aryl Esters of Aromatic Acids," <i>J. Org. Chem.</i> 22 (1957) 325-326.	
	AT	Edwards et. al., "Lewis-acid Catalyzed Reaction of 2-1sopropenylaniline with Ketones: Improved Synthesis of 2,2,4-Trisubstituted 1,2-Dihydroquinolines," <i>Tetrahedron Lett.</i> 39 (1998) 5139-5142.	
	AU	Hayler et. al., "The Design and Synthesis of Thrombin Inhibitors: The Introduction of In Vivo Efficacy and Oral Bioavailability into Benzthiazolyalanine Inhibitors," <i>Bioorg. Med. Chem. Lett.</i> 10 (2000) 1567-1570.	
Examiner signature:		Date considered:	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

SUBSTITUTE FOR FORM 1449/PTO		ATTY. DOCKET NO.: 2002.750 US	SERIAL NO.: 10/540,336
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT: CORNELIS MARIUS TIMMERS ET AL.	
(USE AS MANY SHEETS AS NECESSARY)		EXAMINER NAME: David K. O'Dell	
		FILING DATE: 01/10/2006	ART UNIT: 1625

Sheet 3 of 4

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

Examiner initials*	Cite no. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AV	Jia et al., "Expression of Human Luteinizing Hormone (LH) Receptor: Interaction with LH and Chorionic Gonadotropin from Human but not Equine, Rat, and Ovine Species," <i>Mol. Endo.</i> 5 (1991) 759-768.	
	AW	KNOEVENAGEL, E., "Information on the Ketone Anils, I: Preparation of Aliphatic Ketone Anils and Alkaline Hydrolysis of Ketone Anil Iodoalkylates," <i>Ber. Dtsch. Chen. Gesellschaft</i> 54 (1921) 1722-1730 (English-language translation attached.)	
	AX	Lin et. al., "Substitution Reaction of Tetracyanoethylene with Acetone-Anils," <i>J. Chin. Chem. Soc.</i> 43 (1996) 497-501.	
	AY	Lugovik et. al., "Dokl. Akad. Nauk SSSR, 170:340, 1966 (with English language abstract attached thereto).	
	AZ	Lugovik, B.A., et. al., Khim. Geterosikl. Soedin, 7:795, 1971 (with English language abstract attached thereto).	
	BA	Lugovik, et. al., "Reactions of 1,2-Dihydroxyquinolines IV. Reaction of 2,2,4-Trimethyl-1,2-Dihydroxyquinolines with Cyclohexane," <i>Khimiya geterotsiklichesikh soedinenii</i> 7 (1972) 977-980, (English-language translation attached.)	
	BB	Mellor et. al., "Reaction of Electron Rich Alkenes with Anilines and Formaldehyde: Syntheses of Tetrahydroquinolines," <i>Tetrahedron</i> 51 (1995) 6115-6132.	
	BC	Miyaura et. al., "Palladium-Catalyzed Inter- and Intramolecular Cross-Coupling Reactions of B-Alkyl-9-borabicyclo[3.3.1]none Derivatives with 1-Halo-1-alkenes or Haloarenes," <i>J. Am. Chem. Soc.</i> 111 (1989) 314-321.	
	BD	Montana et. al., "ARYL SULFONAMIDES AS SELECTIVE PDE4 INHIBITORS," <i>Bioorg. Med. Chem. Lett.</i> 8 (1998) 2635-2640.	
	BE	Navot et al., "The Use of Follicle-Stimulating Hormone for Controlled Ovarian Hyperstimulation in <i>in Vitro</i> Fertilization," <i>J. In Vitro Fert. Embryo Transfer</i> 5 (1988) 3-13.	
	BF	Rao, A.J., "Is there a role for contraceptive vaccines in fertility control?", <i>Journal of Bioscience</i> , Vol. 26, No. 4, Suppl., pgs. 425-427 (2001)	
	BG	Schlosser, M., "SELECTIVE MONO- OR DIMETALATION OF ARENES BY MEANS OF SUPERBASIC REAGENTS," <i>Tetrahedron</i> 46 (1990) 5633-5648.	
	BH	Shmyreva et. al., Khim. Tekhnol. 31:45, 1988 (with English language abstract attached thereto).	
	BI	Shmyreva et. al., Obshch. Khim. 59:1391, 1989 (with English language abstract attached thereto).	
	BJ	Stratowa, et al., "Use of a Luciferase Reporter System for Characterizing G-Protein-Linked Receptors," <i>Curr. Opin. Biotech.</i> 6 (1995) 574-581.	

Examiner signature:

Date considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUBSTITUTE FOR FORM 1449/PTO		ATTY. DOCKET NO.: 2002.750 US	SERIAL NO.: 10/540,336
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT: Cornelis Marius Timmers et al.	
(USE AS MANY SHEETS AS NECESSARY)		EXAMINER NAME: David K. O'Dell	FILING DATE: 01/10/2006
		ART UNIT: 1625	

Sheet 4 of 4

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

Examiner initials*	Cite no. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BK	Suzuki, A., "Organoborates in New Synthetic Reactions," <i>Acc. Chem. Res.</i> 15 (1982) 178-184.	
	BL	Walter, H., "Eine neue einfache Synthese spirocyclischer 1H-Chinolin-Derivate," <i>Helv. Chim. Acta</i> 75 (1992) 1274-1280 (with English language abstract attached thereto).	
	BM	Walter, H., "A Novel Approach to 2,2-Disubstituted 1,2-Dihydro-4-phenylquinolines," <i>Helv. Chim. Acta</i> 77; (1994) 608-614.	
	BN	Walter et al., "Acid Catalyzed Reactions of 2-vinylaniline Derivatives with Cyclic Ketones of the Tetralone-, Chroman-4-one- and 2,3-Dihydro-1H-quinolin-4-One Series," <i>Heterocycles</i> 41 (1995) 1251-1269.	
	BO	International Search Report No. PCT/EP03/51024, 30 June 2004	
	BP	Notice of Allowance for U.S. Patent Application No. 10/540,335 mail date 08/14/2009	
	BQ	Non-Final Office Action dated December 5, 2008 for U.S. patent application 10/540,335 filed January 10, 2006	
	BR	RN 339273-93-7 Registry	
	BS	RN 91147-49-8 Registry	
	BT	RN 332904-33-3 Registry	
	BU	International Search Report No. PCT/EP02/07053, 07 October 2002	

Examiner signature:

Date considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2